Lustgarten Foundation funded researchers at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins have designed a multi-analyte blood test that can detect the presence of pancreatic cancer as part of a panel of eight common cancers (pancreas, ovary, liver, stomach, esophagus, colorectum, lung and breast) as reported in the online edition of Science today. The test utilizes combined assays for genetic alterations and protein biomarkers and has the capacity not only to identify the presence of relatively early cancer, but also to localize the organ of origin of these cancers.
“The potential this has for pancreatic cancer is unprecedented,” says Anne Marie Lennon, M.D., Ph.D., Associate Professor of Medicine, Director, Pancreatic Cyst Center of the Ludwig Center at the Johns Hopkins Kimmel Cancer Center. “We know that in 80-85 percent of pancreatic cancer cases, it’s detected too late, leaving the patient with few options. Developing a blood screening test for pancreatic cancer has been an urgent goal, because catching the disease early will be the way we get to long-term survival.”
To view the multimedia release go to:
https://www.multivu.com/players/English/8213751-lustgarten-foundation-pancreatic-cancer-blood-test/
Professor Lionel Tarassenko, CBE, Head of Engineering at the University of Oxford and Fellow of the Royal Academy of Engineering and the Academy of Medical Sciences, has joined a panel of internationally recognised experts for the 3rd Astellas Innovation Debate: i-Genes – What the DNA and Data Revolutions mean for our Health, taking place on Thursday 29th January 2015 at the Royal Institution of Great Britain.
As the worlds of science and technology come together, the 2015 Astellas Innovation Debate, organised and funded by Astellas, will discuss recent breakthroughs in genetic medicine and smart technology, and what they mean for our health.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7432051-lionel-tarassenko-astellas-debate/
http://www.myweightlosssolutions.com
kettering weight loss solutions - kettering weight loss solutions - treating chronic conditio
Top Tips kettering weight loss solutions whipp road
for weight loss do they work :-) Appetite Suppressant - Garcinia Cambogia 1300 - Natural Fat Burner -2B 120Ct with alternate day fasting weight loss results
Also, learn about natural supplements that are sometimes recommended in alternative medicine for weight loss
OPTIFAST® as an Alternative to Weight Loss Surgery 20 Healthy Food Alternatives For Weight Loss
Looking for alternatives to weight loss surgery
Alternate day fasting weight loss calculator
Kettering weight loss solutions - transform your life.
You Should Know About It kettering weight loss solutions whipp road,Fat Burning Kitchen - REVIEW.
2018 - A new study found that you can use alternate day fasting to lose weight and still eat on your fast day alternate day fasting weight loss results.
Check out this alternate day fasting weight loss technique.
Before you do, here are some alternatives to weight loss surgery.
Food list; Healthy junk food recipes; Healthy food substitutes; Junk foods that are actually healthy; Healthy food alternatives for weight loss.
Risk factors, many individuals seeking effective weight loss programs find Cenegenics to be an attractive alternative to weight loss surgery.
2018 - Researchers develop pill alternative to weight loss surgery.
The tapping solution weight loss and body confidence.
Metabolic weight loss solutions reviews.
Beck diet solution weight loss workbook.
Medical weight loss solutions birmingham.
CPhI Worldwide, part of UBM Live’s Pharmaceutical Portfolio, today celebrates its 25th birthday by releasing the first in a series of ‘made at CPhI’ pharma stories. These will follow 25 pharma industry successes that have directly resulted from meetings at CPhI. The first story charts Global Pharmaceutical Relief from a first meeting at CPhI only two years ago to today and providing hundreds of millions of dollars worth of medicines to the developing world via NGOs- not just another business story, but a great example of the CPhI family helping to proliferate healthcare throughout the globe.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/72762554-cphi-worldwide-celebrates-25-years/
TruTag Technologies, Inc., Honolulu-based innovator of an edible security platform to address the trillion dollar global counterfeit problem and the issue of food and medicine safety, has been named a 2014 Technology Pioneer by the World Economic Forum.
To view Multimedia News Release, go to http://www.multivu.com/mnr/63075-trutag-technologies-2014-technology-pioneer-by-world-economic-forum
GW Pharmaceuticals plc (Nasdaq: GWPH, “GW,” “the Company” or “the Group”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, along with its U.S. subsidiary Greenwich Biosciences, announced today that The New England Journal of Medicine has published results from a Phase 3 study of Epidiolex® (cannabidiol) in children with Dravet syndrome.1 Epidiolex, GW’s lead product candidate and the potential first in a new category of anti-epileptic drugs, is a liquid formulation of purified, plant-derived cannabidiol (CBD), a non-psychoactive cannabinoid, which is being studied for the treatment of a number of rare, severe pediatric-onset epilepsy disorders. In the study, Epidiolex significantly reduced monthly convulsive seizure frequency compared to placebo in highly treatment-resistant children when added to existing treatment. Treatment with Epidiolex was generally well tolerated, with a safety profile consistent with prior open label experience.
To view the multimedia release go to:
https://www.multivu.com/players/uk/8109951-gw-pharmaceuticals-study-epidiolex/
Newron Pharmaceuticals S.p.A. (“Newron”), a research and development company focused on novel CNS and pain therapies, and its partner Zambon S.p.A., an international pharmaceutical company strongly committed to the CNS therapeutic area, announced today that the EU Committee for Medicinal Pro-ducts for Human Use (CHMP) recommended that the European Commission approve the use of Xadago™ (safinamide) as add-on to L-dopa alone or in combination with dopamine agonists, entacapone, amantadine, and/or anticholinergics, for the treatment of patients with mid-late stage Parkinson’s disease experiencing motor fluctuations despite being stabilized on ‘Standard of Care’.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7406951-chmp-xadago-parkinsons/
Today, WebMD released The Cutting Edge of Cancer a five-part investigative video series developed in partnership with Robin Roberts and her independent production company, Rock’n Robin Productions. Through compelling patient stories and insights from medical experts, The Cutting Edge of Cancer, supported by Cancer Treatment Centers of America®, highlights some of the most promising areas of medical innovation in cancer care, including early detection, immunotherapy, genomic research, and integrative medicine.
To view the multimedia release go to:
http://www.multivu.com/players/English/7579755-webmd-robin-roberts-cutting-edge-of-cancer/
The Center For Aesthetics
https://thecenterforaesthetics.com
800-575-8337 ~ The CFA Exclusive Evernal Series - Complexion Perfection, laser skincare and hydrafacials. CFA Beauty the premier aesthetic medical centers in Scottsdale, Jackson Hole, Idaho Falls.
Doctors at Qatar’s first specialist women’s and children’s hospital Sidra Medicine have successfully separated conjoined twins, marking a first for the country. The surgery establishes an alternative for patients who previously had limited choices for the successful treatment and care of complex pediatric diseases in the region.
To view the multimedia release go to:
https://www.multivu.com/players/uk/8422651-conjoined-twins-find-new-lease-on-life/
Today Safe Kids Worldwide released a new research report that found kids are getting into medicine at an alarming rate. Every minute of every day, a poison control center receives a call about a potential medicine poisoning for a child age five and under. And 67,000 times each year, or every eight minutes, a young child goes to the emergency room for medicine poisoning. This is a 30 percent increase over the past ten years.
In its report entitled An In-Depth Look at Keeping Young Children Safe Around Medicine, Safe Kids examines data from the U.S. Consumer Product Safety Commission, information from poison control centers and findings from several focus groups among moms. The report reviews what is happening in households that leads to these disturbing numbers and offers parents simple things they can do to protect their children.
To view Multimedia News Release, go to http://www.multivu.com/mnr/60845-safe-kids-worldwide-keeping-young-children-safe-around-medicine
Combining their expertise in clinical trials support and cellular therapies, BloodCenter of Wisconsin (BCW) and the San Diego Blood Bank (SDBB) have created a strategic partnership to accelerate advancements in research and patient care. Together, BloodCenter of Wisconsin and San Diego Blood Bank will offer Celluvative™ – a portfolio of products and clinical trial services that will include esoteric laboratory testing, blood products for research and manufacturing applications, cell processing, and access to a broad database of diverse donors who have expressed interest in clinical trials.
“Through the strength of our partnership, we are able to offer end-to-end services to academic organizations, research institutions and other industry partners who are working to develop novel cellular therapy approaches,” said Matthew Anderson, M.D., Ph.D., medical director, BloodCenter of Wisconsin Diagnostic Laboratories. “Among other offerings, our Celluvative portfolio enables access to an extremely diverse donor database – an invaluable resource to enable advances in the area of regenerative medicine and drug discovery.”
To view the multimedia release go to:
http://www.multivu.com/players/English/7855451-bloodcenter-sdbb-celluvative/
